A total of 140 MS patients were available for the study, of whom 92 were heterozygous for at least one of the three SNPs studied; i.e. rs11052877 (CD69), rs907091 (IKZF3) and rs11609 (IQGAP1), and therefore included in the analyses. The gene discussed is CD69; the disease is myeloid sarcoma.